



Human Renal Cell Systems to advance kidney disease research and renal toxicity screening

September 7, 2011

RESEARCH TRIANGLE PARK, NC - ZenBio, Inc., a privately held biotechnology company, introduces Human Renal Proximal Convoluted Tubule Epithelial Cells (RPCTs) as a biologically relevant, cell-based research tool to study a wide variety of conditions related to kidney disease, renal complications resulting from diabetes as well as renal toxicities and basic cellular functions in the human kidney. Peter Pieraccini, President of ZenBio, Inc. notes, "Our introduction of human renal cells are a natural complement to our existing cell-based systems ZenBio offers to study metabolic diseases and related disorders. The renal cell systems also fit nicely with our continuing efforts in developing cell-based screening models relevant to drug discovery programs to evaluate renal toxicities using primary human cells."

Renal Diseases and disorders are an ongoing global health issue with more than 20 million Americans over 20 years of age having Chronic Kidney Disease (CKD) and over half a million people are undergoing treatment for End-stage Renal Disease (ESRD) in the United States alone. Among the ESRD patients, a majority of these cases are a result of complications from diabetes. Efforts to elucidate pathologies and disease progression associated with renal diseases, continues. Relevant, more effective research tools are needed to examine these pathological processes along with basic renal cell functions.

Renal Proximal Convoluted Tubule Epithelial Cells (RPCTs) are available in a variety of formats including cryopreserved at 500,000 cells/vial along with culture media specifically formulated to support survival and expansion of primary cells *in vitro*. Custom cell-based solutions are also available utilizing the RPCT system based upon project requirements. Contact ZenBio, Inc. for details and a consultation.

Zen-Bio, Inc. Zen-Bio, Inc. (ZB) is a leading global provider of advanced cell-based solutions and services to the life science, cosmetics, and personal care communities. The company, founded in 1995, was a pioneer in adipose derived stem cells (ASCs) and continues this legacy by providing cutting edge human primary cell culture products and services. Our mission is to provide the highest quality human cell systems, reagents and contract services to our research partners; to develop and commercialize innovative research tools, leverage our expertise through research and development and strategic alliances that accelerate discovery.

For more information visit the company website at www.zen-bio.com or call (919)-547-0692; or e-mail Will Plentl, Director of Business Development at will@zenbio.com.

ZenBio, Inc.

3200 Chapel Hill-Nelson Blvd. Suite 104 • P.O. Box 13888 • Research Triangle Park, North Carolina 27709
Toll free: 1-866-ADIPOSE • Phone: (919) 547-0692 • FAX (919) 547-0693
[http:// www.zenbio.com](http://www.zenbio.com) • e-mail: information@zenbio.com